References
- Amini, M., F. Zayeri, and M. Salehi. 2021. Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: Results from global burden of disease study 2017. BMC Public Health 21 (1):401–12. doi:https://doi.org/10.1186/s12889-021-10429-0.
- Bianchini, E. P., R. N. Pike, and B. F. Le Bonniec. 2004. The elusive role of the potential factor X cation-binding exosite-1 in substrate and inhibitor interactions. The Journal of Biological Chemistry 279 (5):3671–9. doi:https://doi.org/10.1074/jbc.M309691200.
- Cer, R. Z., U. Mudunuri, R. Stephens, and F. J. Lebeda. 2009. IC50-to-Ki: A web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding. Nucleic Acids Research 37 (Web Server issue):W441–5. doi:https://doi.org/10.1093/nar/gkp253.
- Chamoles, N. A., M. Blanco, D. Gaggioli, and C. Casentini. 2002. Tay-Sachs and Sandhoff diseases: Enzymatic diagnosis in dried blood spots on filter paper: Retrospective diagnoses in newborn-screening cards. Clinica Chimica Acta 318 (1–2):133–7. doi:https://doi.org/10.1016/S0009-8981(02)00002-5.
- Chen, T. R., L. H. Wei, X. Q. Guan, C. Huang, Z. Y. Liu, F. J. Wang, J. Hou, Q. Jin, Y. F. Liu, P. H. Wen, et al. 2019. Biflavones from Ginkgo biloba as inhibitors of human thrombin. Bioorganic Chemistry 92 (103199):103199–10. doi:https://doi.org/10.1016/j.bioorg.2019.103199.
- Choudhari, P. B., M. S. Bhatia, S. D. Jadhav, S. S. Kumbhar, K. B. Ingale, and V. L. Gaikwad. 2016. Design and development of potent and selective factor IXa inhibitors. Journal of the Taiwan Institute of Chemical Engineers 68:130–5. doi:https://doi.org/10.1016/j.jtice.2016.09.036.
- Chu, X. P., Q. F. Zhou, S. Zhao, F. F. Ge, M. Fu, J. P. Chen, and T. Lu. 2013. Synthesis and biological evaluation of 3-amino-2-pyrones as selective cyclooxygenase-1 (COX-1) inhibitors. Chinese Chemical Letters 24 (2):120–2. doi:https://doi.org/10.1016/j.cclet.2013.01.005.
- Cicalini, I., B. De Filippis, N. Gambacorta, A. Di Michele, S. Valentinuzzi, A. Ammazzalorso, D. Valle, R. Amoroso, O. Nicolotti, P. Del Boccio, et al. 2020. Development of a rapid mass spectrometric determination of AMP and cyclic AMP for PDE3 activity study: Application and computational analysis for evaluating the effect of a novel 2-oxo-1,2-dihydropyridine-3-carbonitrile derivative as PDE-3 inhibitor. Molecules 25 (8):1817–4. doi: https://doi.org/10.3390/molecules25081817. doi:https://doi.org/10.3390/molecules25081817.
- Engel, R., C. M. Brain, J. Paget, A. S. Lionikiene, and N. J. Mutch. 2014. Single-chain factor XII exhibits activity when complexed to polyphosphate. Journal of Thrombosis and Haemostasis : JTH 12 (9):1513–22. doi:https://doi.org/10.1111/jth.12663.
- Gelb, M. H., F. Turecek, C. R. Scott, and N. A. Chamoles. 2006. Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. Journal of Inherited Metabolic Disease 29 (2–3):397–404. doi:https://doi.org/10.1007/s10545-006-0265-4.
- Greis, K. D. 2007. Mass spectrometry for enzyme assays and inhibitor screening: An emerging application in pharmaceutical research. Mass Spectrometry Reviews 26 (3):324–39. doi:https://doi.org/10.1002/mas.20127.
- Holt, T. G., B. K. Choi, N. S. Geoghagen, K. K. Jensen, Q. Luo, W. A. LaMarr, G. M. Makara, L. Malkowitz, C. C. Ozbal, Y. Xiong, et al. 2009. Label-free high-throughput screening via mass spectrometry: A single cystathionine quantitative method for multiple applications. Assay and Drug Development Technologies 7 (5):495–506. doi:https://doi.org/10.1089/adt.2009.0200.
- Hu, Z., C. Wang, W. Han, K. A. Rossi, J. M. Bozarth, Y. Wu, S. Sheriff, J. E. Myers, Jr., J. M. Luettgen, D. A. Seiffert, et al. 2018. Pyridazine and pyridazinone derivatives as potent and selective factor XIa inhibitors. Bioorganic & Medicinal Chemistry Letters 28 (6):987–92. doi:https://doi.org/10.1016/j.bmcl.2018.02.049.
- Ilin, I., E. Lipets, A. Sulimov, D. Kutov, K. Shikhaliev, A. Potapov, M. Krysin, F. Zubkov, L. Sapronova, F. Ataullakhanov, et al. 2019. New factor Xa inhibitors based on 1,2,3,4-tetrahydroquinoline developed by molecular modelling. Journal of Molecular Graphics & Modelling 89:215–24. doi:https://doi.org/10.1016/j.jmgm.2019.03.017.
- Keihanian, F., A. Saeidinia, R. K. Bagheri, T. P. Johnston, and A. Sahebkar. 2018. Curcumin, hemostasis, thrombosis, and coagulation. Journal of Cellular Physiology 233 (6):4497–511. doi:https://doi.org/10.1002/jcp.26249.
- Keith, C. T., A. A. Borisy, and B. R. Stockwell. 2005. Multicomponent therapeutics for networked systems. Nature Reviews. Drug Discovery 4 (1):71–8. doi:https://doi.org/10.1038/nrd1609.
- Lazarova, T. I., L. Jin, M. Rynkiewicz, J. C. Gorga, F. Bibbins, H. V. Meyers, R. Babine, and J. Strickler. 2006. Synthesis and in vitro biological evaluation of aryl boronic acids as potential inhibitors of factor XIa. Bioorganic & Medicinal Chemistry Letters 16 (19):5022–7. doi:https://doi.org/10.1016/j.bmcl.2006.07.043.
- Liu, H. C., S. Z. Tang, S. Lu, T. Ran, J. Wang, Y. M. Zhang, A. Y. Xu, T. Lu, and Y. D. Chen. 2015. Studies on [5,6]-fused bicyclic scaffolds derivatives as potent dual B-RafV600E/KDR inhibitors using docking and 3D-QSAR approaches. International Journal of Molecular Sciences 16 (10):24451–74. doi:https://doi.org/10.3390/ijms161024451.
- Marangoni, A., M. G. Capretti, M. De Angelis, P. Nardini, M. Compri, C. Foschi, A. Orlandi, C. Marsico, F. Righetti, G. Faldella, et al. 2014. Evaluation of a new protocol for retrospective diagnosis of congenital toxoplasmosis by use of Guthrie cards. Journal of Clinical Microbiology 52 (8):2963–70. doi:https://doi.org/10.1128/JCM.00106-14.
- Moreira, H. S., G. A. Lima-Leal, J. Santos-Rocha, L. Gomes-Pereira, G. P. Duarte, and F. E. Xavier. 2018. Phosphodiesterase-3 inhibitor cilostazol reverses endothelial dysfunction with ageing in rat mesenteric resistance arteries. European Journal of Pharmacology 822:59–68. doi:https://doi.org/10.1016/j.ejphar.2018.01.019.
- Perzborn, E., S. Roehrig, A. Straub, D. Kubitza, W. Mueck, and V. Laux. 2010. Rivaroxaban: A new oral factor Xa inhibitor. Arteriosclerosis, Thrombosis, and Vascular Biology 30 (3):376–81. doi:https://doi.org/10.1161/ATVBAHA.110.202978.
- Pochet, L., A. C. Servais, E. Farcas, V. Bettonville, C. Bouckaert, and M. Fillet. 2013. Determination of inhibitory potency of argatroban toward thrombin by electrophoretically mediated microanalysis. Talanta 116:719–25. doi:https://doi.org/10.1016/j.talanta.2013.07.030.
- Qureshi, S. H., L. K. Yang, C. Manithody, A. V. Iakhiaev, and A. R. Rezaie. 2009. Mutagenesis studies toward understanding allostery in thrombin. Biochemistry 48 (34):8261–70. doi:https://doi.org/10.1021/bi900921t.
- Rathore, R., P. Pribil, J. J. Corr, W. L. Seibel, A. Evdokimov, and K. D. Greis. 2010. Multiplex enzyme assays and inhibitor screening by mass spectrometry. Journal of Biomolecular Screening 15 (8):1001–7. doi:https://doi.org/10.1177/1087057110363824.
- Robert, S., C. Bertolla, B. Masereel, J. M. Dogne, and L. Pochet. 2008. Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. Journal of Medicinal Chemistry 51 (11):3077–80. doi:https://doi.org/10.1021/jm8002697.
- Schmidt, A. E., M. F. Sun, T. Ogawa, S. P. Bajaj, and D. Gailani. 2008. Functional role of residue 193 (chymotrypsin numbering) in serine proteases: Influence of side chain length and beta-branching on the catalytic activity of blood coagulation factor XIa. Biochemistry 47 (5):1326–35. doi:https://doi.org/10.1021/bi701594j.
- Selwyn, A. P. 2003. Prothrombotic and antithrombotic pathways in acute coronary syndromes. The American Journal of Cardiology 91 (12):3–11. H. doi:https://doi.org/10.1016/S0002-9149(03)00428-4.
- Skrinjar, P., M. Schwarz, S. Lexmuller, T. P. Mechtler, M. Zeyda, S. Greber-Platzer, J. Trometer, D. C. Kasper, and H. Mikula. 2018. Rapid and modular assembly of click substrates to assay enzyme activity in the newborn screening of lysosomal storage disorders. ACS Central Science 4 (12):1688–96. doi:https://doi.org/10.1021/acscentsci.8b00668.
- Straube, A., B. Aicher, B. L. Fiebich, and G. Haag. 2011. Combined analgesics in (headache) pain therapy: Shotgun approach or precise multi-target therapeutics? BMC Neurology 11 (43):43–15. doi:https://doi.org/10.1186/1471-2377-11-43.
- Su, Y., X. Cheng, and Q. Dong. 2015. Dual antiplatelet therapy of clopidogrel and aspirin in secondary prevention of ischemic stroke: Evidence and indications. CNS Neuroscience & Therapeutics 21 (11):870–6. doi:https://doi.org/10.1111/cns.12419.
- Sudo, T., K. Tachibana, K. Toga, S. Tochizawa, Y. Inoue, Y. Kimura, and H. Hidaka. 2000. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochemical Pharmacology 59 (4):347–56. doi:https://doi.org/10.1016/S0006-2952(99)00346-9.
- Syed, A. A., K. L. Venkatraman, and A. Mehta. 2019. An anticoagulant peptide from Porphyra yezoensis inhibits the activity of factor XIIa: In vitro and in silico analysis. Journal of Molecular Graphics & Modelling 89:225–33. doi:https://doi.org/10.1016/j.jmgm.2019.03.019.
- U.S. Department of Health and Human, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine, (CVM). 2018. Guidance for industry, bioanalytical method validation.
- Xu, Z., R. Liu, and H. Guan. 2017. Dual-target inhibitor screening against thrombin and factor Xa simultaneously by mass spectrometry. Analytica Chimica Acta 990:1–10. doi:https://doi.org/10.1016/j.aca.2017.07.063.
- Yanachkov, I. B., H. Chang, M. I. Yanachkova, E. J. Dix, M. A. Berny-Lang, T. Gremmel, A. D. Michelson, G. E. Wright, and A. L. Frelinger. 2016. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. European Journal of Medicinal Chemistry 107:204–18. doi:https://doi.org/10.1016/j.ejmech.2015.10.055.